发明名称 ELEVATED CCL19 AFTER COMPLETION OF THERAPY FOR ACUTE LYME DISEASE IDENTIFIES PATIENTS AT RISK FOR DEVELOPMENT OF POST-TREATMENT LYME DISEASE SYNDROME WHO WILL BENEFIT FROM FURTHER ANTIBIOTIC THERAPY
摘要 The present invention relates to the field of Lyme disease. More specifically, the present invention provides methods and composition useful for the treatment of Lyme disease. In one aspect, the present invention provides compositions and methods for treating a patient at risk for or likely to develop post-treatment Lyme disease syndrome (PTLDS). In certain embodiments, the patient is already undergoing a first course of antibiotic treatment for Lyme disease. In a specific embodiment, a method comprises the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.
申请公布号 US2016305956(A1) 申请公布日期 2016.10.20
申请号 US201615131063 申请日期 2016.04.18
申请人 THE JOHNS HOPKINS UNIVERSITY 发明人 Aucott John N.;Soloski Mark J.
分类号 G01N33/68;A61K31/65 主分类号 G01N33/68
代理机构 代理人
主权项 1. A method for treating a patient likely to develop post-treatment Lyme disease syndrome (PTLDS) and who is currently undergoing a first course of antibiotic treatment for Lyme disease comprising the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.
地址 Baltimore MD US